We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Irinotecan Plus Cisplatin Therapy and S-1 Plus Cisplatin Therapy for Advanced or Recurrent Gastric Cancer in a Single Institution.
- Authors
Nakashima, Koji; Hironaka, Shuichi; Boku, Narikazu; Onozawa, Yusuke; Fukutomi, Akira; Yamazaki, Kentaro; Yasui, Hirofumi; Taku, Keisei; Kojima, Takashi; Machida, Nozomu
- Abstract
Background: From the results of the JCOG9912 and SPIRITS trials, S-1 plus cisplatin (CDDP) therapy (SP) has been recognized as the standard chemotherapy for advanced gastric cancer in Japan. However, in their subsets of patients with the target lesion, irinotecan (CPT-11) plus CDDP therapy (IP) resulted in longer survival than 5-fluorouracil alone while SP exhibited a survival similar to S-1 alone. The objective of this study was to clarify the safety and efficacy of these two regimens.
- Publication
Japanese Journal of Clinical Oncology, 2008, Vol 38, Issue 12, p810
- ISSN
0368-2811
- Publication type
Article
- DOI
10.1093/jjco/hyn109